2 results
Approved WMOCompleted
To improve symptomatology in severe chronic failure patients.
Approved WMORecruiting
Primary ObjectiveTo demonstrate that avelumab in combination with axitinib is superior to sunitinib monotherapy in prolonging PFS or OS in the first-line treatment of PD-L1 positive patients with aRCC.Secondary Objectives* To demonstrate that…